I sure hope you are right Drafter. The last time BLT announced the Gradalis results, saying ddRNAi was safe and effective, resulted in 130M shares traded but only raised the sp from 2c to 2.3c by day's end. By the end of trade the following day the price was back down to 2c.
So the key would seem to be, will the next announcement be sufficient to make big pharma take note because the first announcement didn't stir up any other interest.
I guess one advantage this time around will be that we now have a business development manager whose job it is to maximise the benefits of a positive Gradalis announcement. Previously, PF could only do this part-time.
Going down memory lane it is also interesting to note that at the end of Dec 2011 the sp was 1.5c. Just before that it was 1.3c. This year looks on track to be the same. So we have not gone backwards but we definitely have not made any headway sp wise despite having nothing but positive announcements and quite a number of them throughout the year. Also, if you overlay the ASX performance for the year over BLT's you find that the two are in sync until Aug this year when the ASX went north and BLT went south. Aug was the publication of our preliminary annual report. One could draw the conclusion that investors were not happy with what the report had to say.
Let's hope it is not to late to get a Christmas present this year that will turn around this trend.
BLT Price at posting:
35.0¢ Sentiment: Hold Disclosure: Held
